At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
EQ101drug
Likely dose
EQ101 2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating EQ101 for Alopecia Areata and 3 related conditions. Completed, enrolled 36 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
CountriesAustralia, New Zealand
CollaboratorsEquillium AUS Pty Ltd
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartDec 2022
Primary CompletionMar 2024
Study CompletionApr 2024
TodayJul 2026
First PostedOct 21, 2022
Enrollment StartDec 19, 2022
Primary CompletionMar 26, 2024
Study CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.7 years ago
Interventions
EQ101drug
EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses